169 related articles for article (PubMed ID: 11571235)
1. Revascularization versus implantable cardioverter-defibrillators to prevent sudden death in patients with severe left ventricular dysfunction.
Weintraub WS
Circulation; 2001 Sep; 104(13):1457-8. PubMed ID: 11571235
[No Abstract] [Full Text] [Related]
2. Time dependence of defibrillator benefit postcoronary revascularization.
Pascale P; Fromer M
J Am Coll Cardiol; 2007 Jan; 49(1):124-5; author reply 125. PubMed ID: 17207734
[No Abstract] [Full Text] [Related]
3. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
[TBL] [Abstract][Full Text] [Related]
4. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Goldenberg I; Moss AJ; McNitt S; Zareba W; Hall WJ; Andrews ML; Wilber DJ; Klein HU;
J Am Coll Cardiol; 2006 May; 47(9):1811-7. PubMed ID: 16682305
[TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter defibrillator therapy for patients with less severe left ventricular dysfunction.
Exner DV
Curr Opin Cardiol; 2009 Jan; 24(1):61-7. PubMed ID: 19077818
[TBL] [Abstract][Full Text] [Related]
6. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Implantable cardioverter defibrillator implantation guidelines based solely on left ventricular ejection fraction do not apply to adults with congenital heart disease.
Triedman JK
Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):307-16; discussion 316. PubMed ID: 19808423
[No Abstract] [Full Text] [Related]
7. [Sudden cardiac death in patients with left ventricular dysfunction from ischemic heart disease: role of the implantable defibrillator. Evidence, guidelines and good clinical judgment].
Serdoz LV; Fabris E; Lutman C; Merlo M; Zecchin M; Sinagra G
G Ital Cardiol (Rome); 2012 Sep; 13(9):592-601. PubMed ID: 22825344
[TBL] [Abstract][Full Text] [Related]
8. Selecting patients for an implantable cardioverter-defibrillator: can the genie be put back into the bottle?
Mittal S
J Am Coll Cardiol; 2008 Jan; 51(3):297-9. PubMed ID: 18206739
[No Abstract] [Full Text] [Related]
9. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
Goldenberg I; Moss AJ; McNitt S; Zareba W; Andrews ML; Hall WJ; Greenberg H; Case RB;
Am J Cardiol; 2006 Aug; 98(4):485-90. PubMed ID: 16893702
[TBL] [Abstract][Full Text] [Related]
10. Cardiac defibrillators, Kant, and the categorical imperative.
Ribeiro AL; Duarte RH
Am Heart J; 2008 Feb; 155(2):e15; author reply e17. PubMed ID: 18215579
[No Abstract] [Full Text] [Related]
11. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention: a necessity after myocardial infarction with left ventricular dysfunction.
Valk S; Jordaens L
Europace; 2009 Apr; 11(4):407-8. PubMed ID: 19279027
[No Abstract] [Full Text] [Related]
13. The editor's roundtable: Implantable cardioverter-defibrillators in primary prevention of sudden cardiac death and disparity-related barriers to implementation.
Friedewald VE; Fonarow GC; Olshansky B; Yancy CW; Roberts WC
Am J Cardiol; 2011 Feb; 107(4):583-90. PubMed ID: 21295175
[No Abstract] [Full Text] [Related]
14. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic implantable cardioverter-defibrillators after myocardial infarction--not for everyone.
Gillis AM
N Engl J Med; 2004 Dec; 351(24):2540-2. PubMed ID: 15590957
[No Abstract] [Full Text] [Related]
16. Implantable defibrillators and sudden cardiac death.
Josephson M; Wellens HJ
Circulation; 2004 Jun; 109(22):2685-91. PubMed ID: 15184292
[No Abstract] [Full Text] [Related]
17. The contradiction of appropriate shocks in primary prevention ICDs: increasing and decreasing the risk of death.
Sweeney MO
Circulation; 2010 Dec; 122(25):2638-41. PubMed ID: 21135359
[No Abstract] [Full Text] [Related]
18. Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators.
Bunch TJ; Hohnloser SH; Gersh BJ
Circulation; 2007 May; 115(18):2451-7. PubMed ID: 17485594
[No Abstract] [Full Text] [Related]
19. Implanted cardioverter defibrillators for the prevention of sudden death.
Dorian P; Talajic M; Tang A
Can J Cardiol; 2005 May; 21 Suppl A():31A-36A. PubMed ID: 15953942
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004.
Al-Khatib SM; Sanders GD; Mark DB; Lee KL; Bardy GH; Bigger JT; Buxton AE; Connolly S; Kadish A; Moss A; Feldman AM; Ellenbogen KA; Singh S; Califf RM;
Am Heart J; 2005 Jun; 149(6):1020-34. PubMed ID: 15976783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
